Synthon opens state-of-the-art laboratory for biotechnology

24-May-2011 - Netherlands

Synthon opened its state-of-the-art laboratory for biotechnology, an important step in the company’s development into a ‘specialty pharmaceutical’ firm. Ms. Renée Bergkamp, Director-General of Enterprise and Innovation of the Ministry of Economic Affairs, Agriculture and Innovation, and Mr. Thom de Graaf, Mayor of Nijmegen, attended the official opening.

“With this new building, Synthon has significantly expanded its scientific infrastructure, putting us in an excellent position to fulfill our far-reaching ambitions in the field of biotechnological products,” says Rudy Mareel, CEO. “Our high-quality generic medicines and the new building allow us to continue developing as complete a portfolio as possible for our most important therapeutic areas: Multiple Sclerosis (MS) and Oncology.”

The new building will be home to around 130 R&D staff, and the 6,850 m2 surface area includes two floors with 1000 m2 of laboratory space. Thanks to a unique collaboration between the parties involved, the building was erected in a record time of less than a year. The work was done with a specific construction team, a fixed budget and complete financial transparency. Construction even started during the design stage and the entire process was conducted according to Lean Construction principles, resulting in enormous efficiency savings.

https://www.bionity.com/en/news/132628/synthon-opens-state-of-the-art-laboratory-for-biotechnology.html